Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.69 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955295 | 0.83 | MCOLN3 (0.51) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL11410923 | 0.82 | ALDH1A1 (0.63) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL5766439 | 0.81 | ALDH1A1 (1.00) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL6215796 | 0.81 | VCAM1 (1.00) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL11651298 | 0.81 | ALDH1A1 (0.67) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL26548006 | 0.81 | ALDH1A1 (0.67) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL11442100 | 0.81 | VCAM1 (0.61) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL29397077 | 0.80 | MCOLN3 (0.58) | ALDH1A1HTTMEN1KMT2AKDM4E | |
| SCHEMBL10700954 | 0.80 | MCOLN3 (0.58) | ALDH1A1HTTMEN1PKMKMT2A | |
| SCHEMBL994972 | 0.80 | MCOLN3 (0.58) | ALDH1A1HTTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-6750217-B2 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS; KINASE INHIBITOR | WARNER-LAMBERT COMPANY | 2004-06-15 | — | — | US | disclosed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2003-05-15 | — | — | US | disclosed |
| US-6440966-B1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-4990523-A | Treatment of chronic inflammatory joint disease with arylsulfonamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-02-05 | — | — | US | disclosed |
| WO-1990015600-A2 | TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | NR2E1, NR0B1, NR0B2 | ALDH1A1 3369/4885VCAM1 1605/4885HTT 2732/4885 |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | ALDH1A1 2773/4885VCAM1 2587/4885HTT 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.